Please assess the completion status of the following clinical trial:

Trial Title: A Confirmatory Study Confirming Performance of a New Intermittent Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male~2. Is at least 18 years of age and has full legal capacity~3. Has given written informed consent~4. Has signed letter of authority (only DK)~5. Has used clean intermittent self-catheterisation (CISC) for at least the last 3 months~6. Has used intermittent catheterisation as the only bladder emptying method for at least the last 3 months~7. Self-catheterise using Coloplast SpeediCath Flex or Hollister VaPro catheters, CH12 or CH14, for at least 3 months prior to inclusion~8. Ability (assessed by investigator) and willingness to adhere to a 2-month study period~Exclusion Criteria~1. Participation in any other clinical study during this investigation~2. Previous participation in this study~3. Symptoms of urinary tract infection as judged by the investigator (rescheduling allowed within recruitment period for LPI)~4. Individuals with history, suspected or showing signs of producing urine with excessive amount of mucus or large/clustered sediments or debris~5. Any known allergies towards ingredients in the investigational device

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Investigational device - intermittent catheter with micro-hole zone (Type: EXPERIMENTAL): Ready-to-use, sterile, hydrophilic coated intermittent male catheter (sizes CH12 and CH14) with a flexible tip and a micro-hole zone for urinary drainage. The investigational device is for single use.
- Comparator device - standard intermittent catheter (Type: ACTIVE_COMPARATOR): Single-use, hydrophilic coated intermittent male catheters (sizes CH12 and CH14) with sleeves: SpeediCath Flex, VaPro, VaPro Pocket, VaPro Plus and VaPor Plus Pocket.

Based on this trial design, predict the completion outcome and termination type (if applicable).